JP2018506995A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506995A5
JP2018506995A5 JP2017562971A JP2017562971A JP2018506995A5 JP 2018506995 A5 JP2018506995 A5 JP 2018506995A5 JP 2017562971 A JP2017562971 A JP 2017562971A JP 2017562971 A JP2017562971 A JP 2017562971A JP 2018506995 A5 JP2018506995 A5 JP 2018506995A5
Authority
JP
Japan
Prior art keywords
cells
transgene
cell
sequence encoding
dhfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017562971A
Other languages
English (en)
Japanese (ja)
Other versions
JP6947647B2 (ja
JP2018506995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/019288 external-priority patent/WO2016138091A2/en
Publication of JP2018506995A publication Critical patent/JP2018506995A/ja
Publication of JP2018506995A5 publication Critical patent/JP2018506995A5/ja
Application granted granted Critical
Publication of JP6947647B2 publication Critical patent/JP6947647B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017562971A 2015-02-24 2016-02-24 遺伝子改変t細胞の選択方法 Active JP6947647B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562120329P 2015-02-24 2015-02-24
US62/120,329 2015-02-24
US201562120790P 2015-02-25 2015-02-25
US62/120,790 2015-02-25
US201562175794P 2015-06-15 2015-06-15
US62/175,794 2015-06-15
PCT/US2016/019288 WO2016138091A2 (en) 2015-02-24 2016-02-24 Selection methods for genetically-modified t cells

Publications (3)

Publication Number Publication Date
JP2018506995A JP2018506995A (ja) 2018-03-15
JP2018506995A5 true JP2018506995A5 (enExample) 2019-03-14
JP6947647B2 JP6947647B2 (ja) 2021-10-13

Family

ID=56464271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562971A Active JP6947647B2 (ja) 2015-02-24 2016-02-24 遺伝子改変t細胞の選択方法

Country Status (8)

Country Link
US (2) US10808230B2 (enExample)
EP (2) EP3261656B1 (enExample)
JP (1) JP6947647B2 (enExample)
KR (1) KR20170117095A (enExample)
CN (1) CN107667169B (enExample)
AU (2) AU2016222850B2 (enExample)
CA (1) CA2976126A1 (enExample)
WO (1) WO2016138091A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
KR102615825B1 (ko) 2015-03-11 2023-12-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전위효소 폴리펩타이드 및 이의 용도
HK1258218A1 (zh) 2015-09-15 2019-11-08 Board Of Regents, The University Of Texas System T细胞受体(tcr)结合抗体及其应用
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CN109136282A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种hafft1细胞的构建方法
AU2019379604B2 (en) 2018-11-16 2026-04-23 Rapa Therapeutics, Llc Als treatment using induced regulatory T (iTREG) cells
WO2020102726A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Method for manufacturing of human hybrid regulatory t/th2 cells (hybrid treg/th2 cells) from de-differentiated t cells
KR102594009B1 (ko) 2021-02-01 2023-10-24 서울대학교산학협력단 형질전환 생식세포의 제조 방법 및 이를 이용한 형질전환 동물의 제조 방법
EP4408169A4 (en) * 2021-09-30 2025-10-29 Univ Southern California Human hepatocyte culture medium and conditioned medium of in vitro cultured human hepatocyte cells and their uses
CN114740196B (zh) * 2022-04-08 2023-04-18 中南大学湘雅二医院 标志物及其在制备评价机体免疫功能的产品中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2573912C2 (ru) * 2008-10-08 2016-01-27 Интрексон Корпорейшн Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
DK3246042T3 (da) * 2009-11-02 2019-10-14 Univ Emory Lægemiddelresistent immunterapi til behandling af cancer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US8809017B2 (en) * 2011-05-24 2014-08-19 Agency For Science, Technology And Research IRES mediated multicistronic vectors
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
CA2861491C (en) * 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
WO2015075195A1 (en) 2013-11-22 2015-05-28 Cellectis Method of engineering chemotherapy drug resistant t-cells for immunotherapy
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
CA2945388A1 (en) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
KR20200138445A (ko) 2014-04-24 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
US20170333480A1 (en) 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
KR102615825B1 (ko) 2015-03-11 2023-12-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전위효소 폴리펩타이드 및 이의 용도
HK1258218A1 (zh) 2015-09-15 2019-11-08 Board Of Regents, The University Of Texas System T细胞受体(tcr)结合抗体及其应用
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof

Similar Documents

Publication Publication Date Title
JP2018506995A5 (enExample)
Krueger et al. Two sequential activation modules control the differentiation of protective T helper-1 (Th1) cells
US10858660B2 (en) Gold optimized CAR T-cells
Fazilleau et al. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding
Schrama et al. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue
Gattinoni et al. T memory stem cells in health and disease
Strutt et al. Memory CD4+ T-cell–mediated protection depends on secondary effectors that are distinct from and superior to primary effectors
Stritesky et al. The transcription factor STAT3 is required for T helper 2 cell development
TW202134285A (zh) Cd19和cd22嵌合抗原受體及其用途
CN115697387A (zh) 抗bcma嵌合抗原受体的用途
US20210393694A1 (en) Coordinating Gene Expression Using RNA Destabilizing Elements
ES2910227T3 (es) Composición y métodos para la estimulación y expansión de células T
JP2017513520A5 (enExample)
AU2016222850A1 (en) Selection methods for genetically-modified T cells
Suematsu et al. PiggyBac transposon-mediated CD19 chimeric antigen receptor-T cells derived from CD45RA-positive peripheral blood mononuclear cells possess potent and sustained antileukemic function
US20220152107A1 (en) Method for expansion and differentiation of t lymphocytes and nk cells for adoptive transfer therapies
Beltra et al. Enhanced STAT5a activation rewires exhausted CD8 T cells during chronic stimulation to acquire a hybrid durable effector like state
US20220241333A1 (en) Modulation of t cell cytotoxicity and related therapy
Trella et al. CD40 ligand‐expressing recombinant vaccinia virus promotes the generation of CD8+ central memory T cells
Metcalfe et al. Ag85A-specific CD4+ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties
US9234175B2 (en) Creating bioengineered lymph nodes
Curtis et al. Fidelity of pathogen-specific CD4+ T cells to the Th1 lineage is controlled by exogenous cytokines, interferon-γ expression, and pathogen lifestyle
van der Heide et al. Prolonged but finite antigen presentation promotes reversible defects of “helpless” memory CD8+ T cells
TW202400780A (zh) Cd16highcd57highnk-92mi 細胞
Capietto et al. A single MHCII neoepitope mRNA vaccine elicits CD4 T-and B-cell responses promoting endogenous CD8 anti-tumor immunity